康方生物科技に関するコメント

$Hang Seng Index(800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...

$康方生物科技(09926.HK)$ Excellent clinical data, focus on product launch and data disclosure
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.